[HTML] mdpi.com

[HTML][HTML] FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2

A Mostafa, A Kandeil, Y AMM Elshaier, O Kutkat… - Pharmaceuticals, 2020 - mdpi.com
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …
被引用次数：143 相关文章
[PDF] scienceopen.com

[PDF][PDF] FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil, YAMM Elshaier, O Kutkat… - …, 2020 - scienceopen.com
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …
[HTML] nih.gov

[HTML][HTML] FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil, YAMM Elshaier, O Kutkat… - …, 2020 - ncbi.nlm.nih.gov
Background: Drug repositioning is an unconventional drug discovery approach to explore
new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to …

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.

A Mostafa, A Kandeil, O Kutkat, Y Moatasim… - Pharmaceuticals …, 2020 - europepmc.org
Background: Drug repositioning is an unconventional drug discovery approach to explore
new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to …
[PDF] researchgate.net

[PDF][PDF] FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil, YAMM Elshaier, O Kutkat… - …, 2020 - researchgate.net
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil… - Pharmaceuticals …, 2020 - pubmed.ncbi.nlm.nih.gov
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …

FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2.

A Mostafa, A Kandeil, YAMM Elshaier, O Kutkat… - 2020 - cabidigitallibrary.org
Background: Drug repositioning is an unconventional drug discovery approach to explore
new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to …

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil… - Pharmaceuticals …, 2020 - researchdiscovery.drexel.edu
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …
[PDF] academia.edu

[PDF][PDF] FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil, YAMM Elshaier, O Kutkat… - …, 2020 - academia.edu
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …
[PDF] semanticscholar.org

[PDF][PDF] FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

A Mostafa, A Kandeil, YAMM Elshaier… - …, 2020 - pdfs.semanticscholar.org
(1) Background: Drug repositioning is an unconventional drug discovery approach to
explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue …